A5293912
Lapatinib Ditosylate (GW-572016) , ≥98% , 388082-77-7
CAS NO.：388082-77-7
Empirical Formula: C43H42ClFN4O10S3
Molecular Weight: 925.46
MDL number: MFCD09264195
EINECS: 1312995-182-4
| Pack Size | Price | Stock | Quantity |
| 25MG | RMB71.20 | In Stock |
|
| 100MG | RMB151.20 | In Stock |
|
| 250mg | RMB214.40 | In Stock |
|
| 500MG | RMB391.20 | In Stock |
|
| 1g | RMB489.60 | In Stock |
|
| others | Enquire |
Update time: 2022-07-08
PRODUCT Properties
| Melting point: | 240-2420C |
| storage temp. | Sealed in dry,Store in freezer, under -20°C |
| solubility | ≥24.3 mg/mL in DMSO; insoluble in EtOH; insoluble in H2O |
| form | solid |
| color | Light yellow to yellow |
| Water Solubility | Water: Insoluble |
| CAS DataBase Reference | 388082-77-7 |
Description and Uses
Lapatinib, an ErB-1 and ErB-2 dual kinase inhibitor, was launched for the treatment of advanced or metastatic HER2 (ErbB2) positive breast cancer in women who have received prior therapy. The drug was discovered and developed by GlaxoSmithKline and is also currently being evaluated for several additional cancer indications.
Lapatinib Ditosylate (GW572016, GW2016, Tykerb, Tyverb) is a potent EGFR and ErbB2 inhibitor with IC50 of 10.8 and 9.2 nM, respectively.
Safety
| Symbol(GHS) |   GHS07,GHS02 |
| Signal word | Danger |
| Hazard statements | H315-H319-H225 |
| Precautionary statements | P501-P240-P210-P233-P243-P241-P242-P264-P280-P370+P378-P337+P313-P305+P351+P338-P362+P364-P303+P361+P353-P332+P313-P403+P235 |
| Safety Statements | 24/25 |
| HS Code | 29420000 |
